Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRDT | Q58F21 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26031675 | 1.00 | BRDT (0.34) | BRDTALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL26031647 | 0.98 | PLA2G2A (0.34) | BRDTALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL24710861 | 0.97 | ALDH1A1 (0.35) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL22733214 | 0.97 | ALDH1A1 (0.35) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL26031723 | 0.96 | ALOX5 (0.35) | BRDTALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL26031627 | 0.94 | PLA2G2A (0.36) | ALDH1A1MAPTHPGDRAB9ASMN1; SMN2 | |
| SCHEMBL26031695 | 0.93 | BRDT (0.34) | BRDTALOX5PRKDCGPR3PLA2G2A | |
| SCHEMBL26031676 | 0.93 | HCRTR1 (0.34) | BRDTALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL26031684 | 0.93 | HCRTR1 (0.34) | BRDTALDH1A1MAPTHPGDRAB9A | |
| SCHEMBL26031707 | 0.93 | BRDT (0.34) | BRDTALOX5PRKDCGPR3PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12048242-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2024-07-23 | — | — | US | disclosed |
| US-12048242-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2024-07-23 | — | — | US | disclosed |
| US-11744149-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2023-08-29 | — | — | US | disclosed |
| US-11744149-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | IDEMITSU KOSAN CO., LTD. (JP) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744149-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | RER1, LEF1, MLX | BRDT 3882/4885ALDH1A1 1659/4885MAPT 3442/4885 |
| US-12048242-B2 | Compound, material for organic electroluminescent elements, organic electroluminescent element, and electronic device | RER1, LEF1, MLX | BRDT 3882/4885ALDH1A1 1659/4885MAPT 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.